The starting point was NSC158011, a thioamide compound known chemically as N-1-naphthalenyl-2-(phenylthiol) ethane thioamide. Earlier work had identified this molecule as an inhibitor of Cryptosporidium lactate dehydrogenase, or LDH, the enzyme the parasite uses to regenerate the molecular currency NAD+ during its energy-generating fermentation of sugars. Because C. parvum lacks many of the metabolic pathways available to its host cells, it relies heavily on this fermentation route, making LDH an attractive drug target. Blocking the enzyme should, in principle, starve the parasite of usable energy while leaving host metabolism, which can draw on far more flexible pathways, comparatively unharmed. The challenge was that NSC158011 itself was only moderately potent, and like many first-generation enzyme inhibitors it carried liabilities that limited its usefulness as a drug candidate.

To improve on the parent compound, the researchers turned to systematic structural optimization. They constructed a virtual library of 1,440 derivatives of NSC158011, varying the chemical groups attached to the thioamide core in a deliberate, computationally guided fashion. Each virtual candidate was then assessed through molecular docking, a technique that predicts how well a small molecule fits into the three-dimensional structure of its protein target. Docking scores served as a filter: rather than synthesizing the entire library, the team selected 29 derivatives whose predicted binding to the LDH active site looked most promising. This triage strategy, common in modern medicinal chemistry, dramatically reduced the cost and time of the campaign by concentrating laboratory effort on the molecules most likely to succeed.

The synthesis and screening phase delivered a clear signal. Of the 29 derivatives made and tested, eight showed significant inhibitory effects on lactate dehydrogenase, outperforming the original NSC158011. That hit rate, nearly a third of the synthesized compounds, suggests that the docking-based selection was effective and that the thioamide scaffold tolerates substantial modification without losing its ability to engage the enzyme. For the authors, the eight active inhibitors confirmed the central hypothesis of the study: that the anti-parasitic activity of this chemical family flows from its interaction with LDH, and that potency can be improved by tuning the molecule’s fit within the enzyme’s binding pocket.

Enzyme inhibition is only the first hurdle, however. A drug candidate must also reach and act within infected cells without poisoning them. In laboratory tests using cells infected with C. parvum, two of the eight potent LDH inhibitors stood out. Both markedly reduced the number of parasites inside host cells, and both did so with reduced toxicity compared with the parent compound. That combination, stronger anti-parasitic effect alongside a better safety margin, is precisely what medicinal chemists hope to achieve through structure-based optimization, and it elevated the two derivatives to lead compound status in the study.

The next question was whether the compounds could work in living animals, where drug absorption, distribution, and the hostile environment of the gut all complicate the picture. The team used two complementary models. The first was the interferon-gamma knockout mouse, a standard experimental model of cryptosporidiosis in which the absence of this key immune signaling molecule leaves animals highly susceptible to persistent infection. The second was the calf, a natural host for C. parvum and the setting where the parasite inflicts its greatest economic damage in agriculture. In both systems, the derivatives showed potent anti-parasitic effects, reducing the parasite burden established by infection.

Beyond simply lowering parasite counts, the treatment appeared to protect the architecture of the infected intestine. Cryptosporidium infection classically causes atrophy of the intestinal villi, the finger-like projections that absorb nutrients, and this tissue damage contributes substantially to the malnutrition and wasting seen in severe disease. In the treated animals, the researchers observed that the derivatives alleviated this villus atrophy, suggesting that clearing the parasite allows the gut lining to begin recovering. For calves in particular, where cryptosporidiosis can stunt growth and spread rapidly through herds, a therapy that both kills the parasite and limits tissue injury would carry real practical value.

To understand how the compounds produced these broader benefits, the researchers examined molecular markers of gut integrity and inflammation. Treatment was associated with increased expression of three tight junction proteins, ZO-1, Occludin, and Claudin-1, which form the seals between adjacent intestinal cells and are essential for maintaining the barrier that keeps gut contents out of the bloodstream. At the same time, the compounds lowered expression of Caspase-1, an inflammatory protein involved in driving damaging inflammatory responses. Together these changes paint a picture of a gut barrier being restored and inflammation being dialed back as the parasite burden falls, consistent with the observed healing of the villi.

The team also looked one level deeper, at the ecosystem of microbes and metabolites in the gut. Analysis of the gut microbiota in treated calves showed that the derivatives significantly restored the abundance of beneficial flora, the microbial populations associated with healthy digestion and resistance to pathogens. Complementary metabolomic profiling revealed that treatment regulated key metabolites, including isocitric acid, an intermediate of cellular energy metabolism, and ornithine, an amino acid central to the urea cycle and to intestinal tissue repair. These findings suggest that effective anti-parasitic therapy does not operate in isolation: by removing the parasite, the drugs appear to allow the entire gut ecosystem, from microbes to metabolic chemistry, to rebalance itself toward health.

The study’s authors position the two derivatives as promising lead compounds for further development as anti-cryptosporidiosis agents, with relevance both to livestock production and to public health. The path from lead compound to approved drug remains long, requiring optimization of pharmacokinetics, formal safety testing, and clinical or field trials, and the current study does not resolve those questions. But the work demonstrates a complete early-stage pipeline: a validated metabolic target, a computationally guided chemical library, confirmed enzyme inhibition, cellular efficacy with reduced toxicity, and efficacy in both a susceptible mouse model and a natural animal host, with mechanistic evidence of tissue and microbiome recovery. For a disease with few treatment options, particularly nitazoxanide, which performs inconsistently in the malnourished and immunocompromised patients who need it most, any new chemical starting point is significant. If the two derivatives survive the rigors of preclinical and clinical development, they could eventually offer a much-needed option against a parasite that sickens children and calves across the globe.

Subject of Research: Development of lactate dehydrogenase inhibitors as drug candidates against Cryptosporidium parvum

Article Title: Novel inhibitors against Cryptosporidium parvum through blocking its energy metabolism

Article References: Xu, C., Ji, Y., Sha, Q., & Li, K. (2026). Novel inhibitors against Cryptosporidium parvum through blocking its energy metabolism. PLOS Neglected Tropical Diseases, 20(10), e0014742. https://doi.org/10.1371/journal.pntd.0014742

Image Credits: AI Generated

DOI: 10.1371/journal.pntd.0014742

Keywords: Cryptosporidium parvum, lactate dehydrogenase, drug discovery, molecular docking, cryptosporidiosis, intestinal parasite, gut microbiota, metabolomics, tight junction proteins, livestock health, neglected tropical diseases, lead compounds

The first node is the intestinal epithelium, the single-cell-thick lining that decides what passes from the gut lumen into the body. Its integrity depends on tight junctions built from proteins such as claudins and occludins, on a protective mucus layer, and on antimicrobial peptides secreted into the lumen. In Crohn’s disease, disruption of these tight junctions produces the phenomenon known as leaky gut: paracellular leakage that allows microbial antigens to cross into the lamina propria, where they encounter the immune system. Pro-inflammatory cytokines such as tumor necrosis factor-alpha and interleukin-6 can worsen the damage, and a decline in Wnt/beta-catenin signaling, a pathway essential for epithelial proliferation and differentiation, may impair mucus synthesis and tissue repair. The result is a barrier that fails precisely when the tissue needs regeneration most.

The review emphasizes that epithelial cells are not passive bricks in a wall. They actively participate in immune surveillance, secreting cytokines and chemokines such as interleukin-8 that recruit neutrophils to inflammatory sites. When pathobionts such as adherent-invasive Escherichia coli remodel this crosstalk, the recruitment and activation of immune cells becomes distorted, protective pathogen-clearance responses falter, and inflammation deepens. Meanwhile, intracellular signaling systems including NF-kappaB, Notch and PI3K/Akt govern how epithelial cells proliferate, differentiate and respond to stress; NF-kappaB activation during inflammatory interactions can remodel cytokine production and downregulate tight-junction expression, compounding the very barrier defect that triggered it.

The second node is the immune system. In Crohn’s disease, the balance between pro-inflammatory cytokines such as TNF-alpha and interleukin-6 and anti-inflammatory mediators such as interleukin-10 and transforming growth factor-beta tips sharply toward inflammation. T helper 17 cells expand, interleukin-17 mediates tissue injury, and regulatory T cells, the custodians of immune tolerance, lose ground. Chemokines such as CCL2 and CXCL10, which normally direct monocytes and T cells to sites of infection, instead orchestrate a chronic influx of activated immune cells into the gut wall. The review stresses that restoring inflammatory balance without disabling the immune system’s ability to fight infection remains one of the central therapeutic challenges in the field.

The third node is the gut microbiota. In Crohn’s disease, microbial diversity falls, beneficial short-chain fatty acid-producing members of the phylum Firmicutes are depleted, and potential pathobionts, most notably adherent-invasive E. coli, expand. This matters because microbial metabolites are among the most important chemical messengers between the microbiota and the host. Short-chain fatty acids such as acetate, propionate and butyrate, produced by the fermentation of dietary fiber, serve as the primary energy source for colonic epithelial cells, upregulate tight-junction expression, and promote the differentiation of regulatory T cells while suppressing pro-inflammatory Th17 responses through histone deacetylase-dependent mechanisms. When butyrate-producing taxa vanish, the epithelium loses fuel, the immune system loses a brake, and tolerance gives way to activation.

The heart of the review is its description of three positive feedback loops that weld these nodes together. In the IL-23/Th17 axis, interleukin-23 drives Th17 polarization, leading to interleukin-17 secretion, epithelial barrier disruption, microbial translocation and sustained IL-23 release. In the TNF-alpha-driven pathway, TNF-alpha disrupts epithelial tight junctions, enabling pathobiont translocation, TLR4/NF-kappaB activation and amplified TNF-alpha production. In the SCFA depletion cycle, reduced short-chain fatty acid levels impair regulatory T cell differentiation, promoting Th17 dominance, inflammation and further depletion of the very microbes that produce these metabolites. Each loop can, in principle, start anywhere, and once running, any one of them can keep the others alive.

This circuit model carries a pointed therapeutic implication: single-pathway drugs can be highly effective in selected patients, yet persistent activity in other compartments of the circuit may explain why some responses are incomplete or not durable. The clinical evidence reviewed supports this reading. The IL-23 inhibitor risankizumab produced greater endoscopic response than placebo at week 52 in patients with moderate-to-severe Crohn’s disease, including those who had failed anti-TNF therapy, with a relative risk of 3.40 in the ADVANCE/CD-101 program. The oral JAK1 inhibitor upadacitinib demonstrated efficacy for both induction and maintenance in phase 3 trials. For perianal fistulizing disease, darvadstrocel, an adipose-derived stromal-cell therapy, achieved fistula resolution in 56 percent of patients at 24 weeks in the ADMIRE-CD II trial and has been authorized in the European Union and Japan.

Non-drug strategies fit the same framework. The Crohn’s Disease Exclusion Diet, which removes specific food components, has shown efficacy for inducing and sustaining remission in randomized trials of patients with mild-to-moderate disease over 12 to 24 weeks, plausibly by reshaping the microbial and metabolic arm of the circuit. Fiber-rich diets that promote Bifidobacterium and Lactobacillus, SCFA supplementation, and probiotics targeting butyrate-producing taxa all aim to restore the microbial node. The review also flags a broader metabolic dimension: shared pathways involving dysbiosis, barrier impairment and chronic low-grade inflammation suggest that conditions such as Type 2 diabetes and metabolic syndrome should be viewed as potential modifiers of the epithelial-immune-microbiota axis rather than incidental comorbidities.

The framework is explicitly hypothesis-generating rather than a clinical guideline, and the authors are candid about its limits. Animal models such as TNF-delta-ARE mice and AIEC-colonized rodents capture fragments of the disease but none reproduces the full polygenic susceptibility, transmural inflammation and relapsing course seen in patients. A long-standing controversy remains over whether dysbiosis is a primary cause or a secondary consequence of inflammation; the review’s integrative position is that dysbiosis may act as a primary driver in young-onset or treatment-naive disease while functioning mainly as a disease-perpetuating amplifier once inflammation has established a permissive microbial niche. Environmental factors, including high-fat diets and psychological stress, can push the network in either direction by reshaping microbial composition and mucosal immune competence.

Where the framework becomes actionable is in measurement and stratification. Each node of the circuit can be paired with observable indicators: intestinal permeability markers, endoscopic and transmural healing, fecal calprotectin, cytokine profiles, microbial diversity, pathobiont enrichment and metabolite levels. Longitudinal profiling of these measures could, in principle, sort patients into barrier-dominant, immune-dominant, microbiota-dominant or mixed phenotypes, each pointing toward a different therapeutic priority. Multi-omics platforms combining shotgun metagenomics, metabolomics and proteomics, together with machine-learning models such as those predicting endoscopic response to ustekinumab from genomic and transcriptomic data, and AI-assisted endoscopy systems like EndoBrain and CAD-EYE, are already moving in this direction, though the authors caution that most current biomarkers capture only one dimension of disease biology and that cross-sectional observations cannot reliably distinguish primary drivers from secondary consequences. The STRIDE-II treat-to-target recommendations, which emphasize endoscopic healing and, in selected settings, transmural assessment by intestinal ultrasound or MRI, provide the monitoring backbone. What remains to be proven, through longitudinal validation and controlled trials, is whether treatments chosen by mechanism rather than by convention genuinely deliver more durable mucosal healing, lower relapse risk and better lives for people with Crohn’s disease.

Subject of Research: The interplay of epithelial barrier dysfunction, immune dysregulation and gut microbiota dysbiosis in Crohn's disease pathogenesis and therapy

Article Title: Tripartite Interplay of Epithelial, Immune, and Microbiota Dysregulation in Crohn's Disease: Mechanisms and Translational Strategies

Article References: Lai, Q., Zhang, Q.-Y., Yang, W.-P., & Luo, C.-Y. (2026). Tripartite Interplay of Epithelial, Immune, and Microbiota Dysregulation in Crohn's Disease: Mechanisms and Translational Strategies. Immunity, Inflammation and Disease, 14(10), Article e70538. https://doi.org/10.1002/iid3.70538

Image Credits: AI Generated

DOI: 10.1002/iid3.70538

Keywords: Crohn's disease, intestinal epithelial barrier, gut microbiota, Th17 cells, IL-23, TNF-alpha, short-chain fatty acids, AIEC, JAK inhibitors, risankizumab, dysbiosis, precision medicine

The study, published in the journal 3 Biotech by Mao Ye of the Anhui ZHONG-AO Institute of Technology and colleagues at Anhui University of Chinese Medicine, examined hydroxysafflor yellow A, or HSYA, a water-soluble pigment extracted from safflower, a plant long used in traditional Chinese medicine. The researchers combined HSYA treatment with swimming-based aerobic exercise in rats subjected to middle cerebral artery occlusion and reperfusion, a widely used laboratory model of ischemic stroke. Their central finding is striking: the combination therapy acted synergistically, restoring learning and memory, shrinking brain infarcts, repairing the blood-brain barrier, and rebuilding synaptic connections through activation of the HIF-1α/CREB signaling pathway.

To model human stroke, the team used the intraluminal suture method, in which a fine filament is threaded into a blood vessel to block the middle cerebral artery. The rats endured two hours of ischemia before the suture was withdrawn and blood flow was restored, mimicking the clinical sequence of a clot followed by reperfusion therapy. The animals were then divided into four groups: a sham-operated control group, a model group receiving no treatment, a group given HSYA alone, and a group receiving both HSYA and a structured aerobic swimming regimen. This design allowed the researchers to isolate the contribution of each intervention and, crucially, to test whether their effects were additive or genuinely synergistic.

Behavioral testing came first. In the Morris water maze, a standard assay in which rodents must learn the location of a hidden platform using spatial cues, the combination-treated rats located the platform significantly faster than untreated stroke animals, indicating preserved learning and memory. Open field tests, which measure exploratory locomotion and anxiety-like behavior, corroborated the cognitive gains. These functional improvements were not merely subjective impressions; they tracked with hard anatomical evidence. Staining brain sections with 2,3,5-triphenyltetrazolium chloride, a dye that distinguishes living tissue from infarcted tissue, revealed that the combined intervention dramatically reduced the volume of dead brain tissue compared with the untreated model group.

Under the microscope, the differences were equally clear. Hematoxylin and eosin staining showed that neurons in the combination group retained healthier morphology, while TUNEL staining, which flags cells undergoing the programmed death known as apoptosis, demonstrated that far fewer neurons were lost when HSYA and exercise were applied together. The researchers also turned their attention to the blood-brain barrier, the tightly sealed lining of endothelial cells that shields the brain from blood-borne toxins and immune cells. Reperfusion injury is notorious for tearing this barrier open, allowing fluid and inflammatory molecules to flood brain tissue and worsen swelling. Immunofluorescence and Western blot analyses showed that the combination therapy markedly upregulated two key tight junction proteins, ZO-1 and occludin, the molecular rivets that hold barrier cells together, indicating effective structural repair of the damaged barrier.

Perhaps the most clinically exciting results concerned synaptic recovery. Strokes destroy not only neurons but the connections between them, and lasting functional recovery depends on rebuilding those circuits. The combination group showed elevated levels of PSD95, a scaffold protein essential to the receiving side of a synapse; GAP43, a marker of axonal regeneration and growth cone activity; and SYN, or synaptophysin, a protein abundant in synaptic vesicles. Alongside these structural markers, levels of the neurotrophins BDNF and NGF rose as well. These growth factors act as fertilizers for neuronal survival and plasticity, encouraging damaged networks to sprout, rewire, and strengthen. Together, the data suggest the therapy does more than keep neurons alive; it actively promotes the repair of the circuitry underlying memory and movement.

To understand how a safflower pigment and a swimming routine could converge on the same biology, the researchers employed molecular docking, a computational technique that predicts how small molecules fit into the binding pockets of target proteins. Docking simulations suggested that HSYA interacts favorably with HIF-1α, the alpha subunit of hypoxia-inducible factor 1, a master transcriptional regulator that switches on genes helping cells survive low oxygen. Western blotting then confirmed that the combined intervention significantly elevated expression of HIF-1α and of phosphorylated CREB, the cyclic AMP response element-binding protein, a transcription factor central to learning, memory, and long-term synaptic plasticity. The convergence of these two pathways offers a mechanistic explanation for the synergy: the drug and the exercise appear to amplify a shared pro-survival, pro-repair signaling axis.

The HIF-1α/CREB axis is an intriguing therapeutic target because it sits at the intersection of oxygen sensing and neuroplasticity. HIF-1α orchestrates adaptive responses to hypoxia, including angiogenesis and glycolytic metabolism, which can help revascularize and re-energize penumbral tissue after a stroke. CREB, meanwhile, drives the expression of plasticity-related genes, including BDNF, which the study found elevated in the combination group. Exercise is already known to stimulate neurotrophic signaling, and prior work from the same research group and others has linked HSYA to protection of brain microvascular endothelial cells and suppression of mitochondrial apoptosis. The new findings knit these threads together, proposing that pharmacological activation of hypoxia-adaptive signaling and exercise-driven plasticity signaling reinforce one another rather than merely adding up.

The study carries important caveats. It was conducted in rats, and rodent stroke models, while invaluable, have a long history of therapies that succeeded in animals but failed in human trials. The swimming protocol, dosing, and timing of HSYA administration would all need optimization and validation in larger preclinical studies before any translation to patients. Stroke rehabilitation in humans already includes graded aerobic exercise, so the more realistic near-term question is whether HSYA, or related compounds, could be safely layered onto existing rehabilitation programs. Notably, the authors report that the work was supported by a key project under the 2023 Natural Science Research Fund for Universities in Anhui Province, and they declare no conflicts of interest.

Even so, the research adds to a growing body of evidence that multimodal combination strategies, rather than any single magic bullet, may be the key to treating reperfusion injury after stroke. Thrombolytic drugs and mechanical clot retrieval save lives by restoring blood flow, but they do little for the biochemical storm that follows. By simultaneously shoring up the blood-brain barrier with restored tight junctions, boosting neurotrophic support, and engaging the HIF-1α/CREB pathway, the HSYA-plus-exercise regimen offers a template for therapies that address the downstream biology of stroke rather than only its upstream cause. If future studies confirm these mechanisms in larger models and eventually in clinical settings, an ancient safflower pigment, paired with something as accessible as regular aerobic exercise, could become a meaningful piece of the post-stroke recovery puzzle.

Subject of Research: Combined hydroxysafflor yellow A and aerobic exercise therapy for cerebral ischemia-reperfusion injury via the HIF-1α/CREB pathway

Article Title: Combined intervention: hydroxysafflor yellow A acts synergistically with aerobic exercise to alleviate cerebral ischemia-reperfusion injury via the HIF-1α/CREB pathway

Article References: Ye, M., Peng, Y., Sun, H., Shen, X., Wang, Y., & Huang, P. (2026). Combined intervention: hydroxysafflor yellow A acts synergistically with aerobic exercise to alleviate cerebral ischemia-reperfusion injury via the HIF-1α/CREB pathway. 3 Biotech, 16(11), Article 453. https://doi.org/10.1007/s13205-026-05036-y

Image Credits: AI Generated

DOI: 10.1007/s13205-026-05036-y

Keywords: cerebral ischemia-reperfusion injury, hydroxysafflor yellow A, aerobic exercise, HIF-1α/CREB pathway, blood-brain barrier, synaptic plasticity, stroke, neuroprotection, BDNF, tight junction proteins, middle cerebral artery occlusion, neurotrophins

The experimental logic behind the study is rooted in what scientists call the microbiota-gut-brain axis, the bidirectional communication network linking the intestinal microbial community, the gut epithelial barrier, the immune system, and the central nervous system. In recent years, disruptions in this axis have been implicated in a range of neurological conditions, from depression and autism to Parkinson’s and Alzheimer’s disease. In Alzheimer’s specifically, an imbalanced gut microbiota can compromise the intestinal mucosal barrier, allowing bacterial products such as lipopolysaccharides and amyloid-like molecules to circulate, activate microglia, and drive chronic neuroinflammation, which in turn accelerates neurodegeneration.

To model the disease, the researchers injected Wistar albino rats intraperitoneally with aluminium chloride at 50 milligrams per kilogram of body weight and D-galactose at 100 milligrams per kilogram for seven consecutive days. Aluminium is a known neurotoxin that disrupts metal homeostasis and promotes iron-mediated lipid peroxidation, while D-galactose generates reactive oxygen species that damage proteins, lipids, and DNA. Together, the two chemicals reliably produce the pathological signature of Alzheimer’s in rodents: beta-amyloid plaque accumulation, neurofibrillary tangles, declining neurotransmitter levels, and widespread oxidative injury. The team then tested three different probiotic regimens, co-administration alongside the toxins, a prophylactic protocol in which the probiotic preceded the toxins, and a therapeutic protocol in which the probiotic followed the toxin exposure, and compared all of them against a memantine-treated positive control group.

The histopathological results were striking. Congo red staining of brain sections revealed that rats exposed to aluminium chloride and D-galactose developed dense amyloid plaque deposits, cerebral amyloid angiopathy, and neurofibrillary tangles in the hippocampus and cerebral cortex. In the rats that received L. fermentum NCDC701, whether before, during, or after toxin exposure, these abnormalities were markedly reduced, with hippocampal tissue appearing largely normal, cells intact, and no signs of necrosis. Notably, the probiotic-treated groups appeared to outperform memantine, the standard anti-Alzheimer drug used as a positive control, which left some residual plaques and angiopathy. In the colon, haematoxylin and eosin staining showed that the probiotic restored epithelial integrity and reduced the infiltration of inflammatory leukocytes and neutrophils that the toxin regimen had caused.

Biochemical assays using ELISA quantified the molecular shifts underlying these tissue-level changes. The toxin-exposed rats showed elevated concentrations of beta-amyloid peptides 1-40 and 1-42 in both brain and serum, along with depressed levels of the inhibitory neurotransmitter GABA and the monoamine serotonin. Supplementation with L. fermentum NCDC701 reversed both trends, lowering amyloid peptide concentrations and restoring GABA and serotonin toward control levels. This is consistent with the strain’s in vitro profile: the researchers measured GABA production by NCDC701 at approximately 99.43 millimolar, suggesting the bacterium is a substantial neurotransmitter factory. Because GABA decline is considered a contributor to Alzheimer’s symptomatology, and because reduced serotonin has been linked to the aggressive behaviors seen in dementia patients, the neuromodulatory capacity of this strain is of particular interest.

The probiotic also rebalanced the immune chemistry of both brain and colon. Pro-inflammatory cytokines IL-6 and TNF-alpha, which surged after toxin exposure, fell significantly in all three probiotic groups, while the anti-inflammatory cytokine IL-10 rose. At the transcriptional level, RT-qPCR showed that NCDC701 suppressed the expression of p65, a key component of the NF-kappaB inflammatory signaling complex, along with COX-2 and iNOS, two enzymes that amplify inflammatory and oxidative damage, in both brain and colonic tissue. Simultaneously, the strain boosted the activity of the antioxidant enzymes superoxide dismutase, catalase, and glutathione peroxidase, which the toxin regimen had suppressed, thereby restoring the tissue’s capacity to neutralize free radicals.

One of the most clinically relevant findings concerned the gut barrier itself. The mRNA expression of tight junction proteins, zonula occludens-1, occludin, and claudin-1, dropped sharply in the colons of toxin-exposed rats, reflecting a leaky intestinal epithelium that permits bacterial endotoxins to enter circulation. L. fermentum NCDC701 restored the expression of all three proteins, effectively re-sealing the barrier. This matters because a compromised gut lining is thought to be a gateway event in the gut-brain axis model of neurodegeneration: it allows lipopolysaccharides and other microbial products to trigger systemic inflammation, activate microglia in the brain, and promote amyloid aggregation. By reinforcing the barrier, the probiotic may be cutting the disease process off at one of its upstream sources.

Deep sequencing of the V3-V4 region of the 16S rRNA gene in faecal samples revealed how profoundly the toxin regimen disturbed the gut ecosystem, and how effectively the probiotic repaired it. Aluminium chloride and D-galactose lowered the Shannon diversity index and the number of observed operational taxonomic units, signatures of dysbiosis. The Firmicutes to Bacteroidetes ratio, 1.435 in healthy controls, fell to 1.03 in the disease model but rebounded to approximately 1.4 in all probiotic-treated groups. Beneficial genera such as Lactobacillus, Prevotella, Ruminococcus, and Oscillospira, the latter known to support IL-10-producing regulatory T cells, all recovered after probiotic administration, while pathogenic taxa including Spirochaetes, Porphyromonadaceae, Coprococcus, Clostridium, and Allobaculum receded. The disease model also showed elevated Proteobacteria, a phylum increasingly recognized as a microbial marker of dysbiosis and inflammation, which declined with treatment.

Metabolite analysis tied these microbial shifts to functional chemistry. Gas-liquid chromatography of faecal samples showed that the disease model was enriched in propionate, echoing previous reports of elevated propionic acid in the blood of Alzheimer’s patients, while butyrate and total short-chain fatty acids were depressed. Probiotic treatment restored the short-chain fatty acid profile, increasing butyrate, a molecule that fuels colonocytes, strengthens epithelial tight junctions, and can modulate anti-inflammatory pathways through G-protein-coupled receptors. Because short-chain fatty acids can enter the circulation, cross the blood-brain barrier, and influence vagal, endocrine, and immune signaling, their restoration provides a plausible mechanistic bridge between the microbial changes observed in the colon and the biochemical recovery documented in the brain.

The authors are candid about the study’s limitations. The biochemical and molecular analyses used small groups of three animals per condition, a constraint imposed by resource limitations during the COVID-19 pandemic, and no human clinical trials have yet tested the strain. Larger and more diverse cohorts will be needed to confirm the statistical robustness and generalizability of the results, and translational studies will be essential before any commercial application. Nevertheless, the convergence of histological, biochemical, transcriptional, microbiological, and metabolomic evidence around a single probiotic strain is unusual and compelling. If future work validates these findings in humans, L. fermentum NCDC701 could represent a new class of adjunct therapy for Alzheimer’s disease, one that works not by attacking plaques directly in the brain, but by rebuilding the microbial and barrier defenses of the gut, and letting the microbiota-gut-brain axis carry the benefit upward.

Subject of Research: Probiotic modulation of the gut-microbiota-brain axis in an aluminium chloride and D-galactose-induced rat model of Alzheimer's disease

Article Title: Ameliorative action of probiotics on the neurotoxicological effect of Aluminium chloride and D-galactose

Article References: Dasriya, V. L., Kumari, M., Ranveer, S., Behare, P., Vij, S., & Puniya, A. K. (2025). Ameliorative action of probiotics on the neurotoxicological effect of Aluminium chloride and D-galactose. Discover Toxicology, 2(1), Article 6. https://doi.org/10.1007/s44339-025-00022-0

Image Credits: AI Generated

DOI: 10.1007/s44339-025-00022-0

Keywords: probiotics, Limosilactobacillus fermentum, Alzheimer's disease, gut-brain axis, amyloid plaques, neuroinflammation, oxidative stress, GABA, short-chain fatty acids, gut microbiota, tight junction proteins, aluminium chloride

The research team, led by Liang Cao and Mengzhou Xue together with V. Wee Yong, took an unusually comprehensive route to this discovery. Rather than relying on any single line of evidence, they wove together large-scale human genetics, transcriptomics, proteomics, single-cell resolution analysis, and animal experimentation. Their starting point was a familiar frustration in stroke genetics: genome-wide association studies have identified numerous risk loci for intracerebral hemorrhage, but most of these variants sit in non-coding regions of the genome, leaving the actual causal genes and mechanisms shrouded in ambiguity.

To cut through that ambiguity, the investigators deployed transcriptome-wide and proteome-wide association studies, known as TWAS and PWAS, which predict how genetically determined differences in gene expression or protein abundance influence disease risk. They integrated summary statistics from four large hemorrhage GWAS datasets, including a European-ancestry meta-analysis drawing on the FinnGen consortium and UK Biobank, independent FinnGen replication rounds, and the BioBank Japan cohort for trans-ethnic validation. Bayesian colocalization analysis then tested whether the genetic signals for disease and for gene regulation shared the same causal variant, while summary-data-based Mendelian randomization with the HEIDI test helped distinguish genuine causal effects from linkage artifacts.

Several genes emerged from this gauntlet, including ICA1L, WDR12, BAIAP3, MLYCD, CSPG5, SUN2, HABP4, and BID, several of which had never before been linked to hemorrhagic stroke. But one candidate stood apart. In the FinnGen R11 cohort, genetically predicted abundance of the LAMC1 protein was significantly associated with lower hemorrhage risk in two independent brain proteome datasets, and MAGMA gene-level analysis validated the signal. Most tellingly, when the researchers intersected their results across European and East Asian ancestry cohorts using two independent prioritization methods, LAMC1 was the only gene shared between populations, a convergence that substantially strengthens the case for its biological relevance.

The causal evidence deepened from there. Colocalization analysis in two independent brain eQTL datasets, BrainMeta v2 and PsychENCODE, yielded posterior probabilities of 0.923 and 0.934 that the LAMC1 expression signal and the hemorrhage risk signal share a single causal variant, with the lead SNP rs12146099 anchoring both signals on chromosome 1. Similar colocalization appeared in blood-based datasets from GTEx v8 and eQTLGen. Mendelian randomization across all four datasets pointed consistently in the protective direction: each one-standard-deviation increase in genetically predicted LAMC1 expression was associated with an odds ratio for hemorrhage well below 1.0, ranging from 0.873 down to 0.630 depending on the dataset.

Perhaps the most technically impressive step was pinpointing which brain cells actually matter. Because bulk brain tissue masks the signals of its highly heterogeneous cell populations, the team turned to single-cell expression quantitative trait loci datasets and ran colocalization analysis in every major cell type. The result was unambiguous: the genetic signal regulating LAMC1 expression and the hemorrhage risk signal colocalized most strongly within astrocytes, with a posterior probability of 0.956 in the FinnGen R11 analysis. Other genes told different stories, with ICA1L and WDR12 signals localizing to neurons, but LAMC1’s story was one of astrocytes and blood vessels.

Mouse experiments then brought the human genetics to life. Using a collagenase-induced hemorrhage model, the researchers tracked LAMC1 protein over two weeks and found it plummeted after injury, reaching its lowest point on day three, even though mRNA levels stayed flat, hinting that the protein is degraded rather than transcriptionally silenced. Multiplex immunofluorescence revealed exactly where the loss occurred: LAMC1 colocalized with the astrocyte marker GFAP and the endothelial marker CD31, and its signal dropped significantly in both cell types after hemorrhage. Crucially, it showed essentially no overlap with microglia or neurons, indicating a cell-type-specific collapse rather than a generic stress response.

The therapeutic proof came from gene delivery. Three weeks before inducing hemorrhage, mice received adeno-associated virus vectors driving LAMC1 overexpression under a GFAP promoter in the striatum. When hemorrhage was later induced, the treated animals fared markedly better. H&E staining showed preserved striatal architecture and reduced lesion area, brain water content fell significantly in the ipsilateral cortex and basal ganglia, and behavioral tests confirmed functional benefit: mice overexpressing LAMC1 scored higher on the forelimb placing test and stayed on the rotarod significantly longer than controls on day three.

The mechanism traces back to the blood–brain barrier. In an Evans blue extravasation assay, dye that should have been confined to vessels leaked extensively into the injured hemisphere of control mice, but LAMC1-overexpressing animals showed significantly less leakage. Western blotting revealed why: hemorrhage drastically reduced the tight junction proteins ZO-1 and occludin, which seal the gaps between endothelial cells, and LAMC1 overexpression reversed that loss. Immunofluorescence showed the same story visually, with tight junction staining that was fragmented and discontinuous in controls but restored to continuous, linear vascular profiles in treated mice. LAMC1, a laminin gamma chain glycoprotein normally embedded in the basement membrane, appears to physically scaffold the barrier and prevent degradation of its molecular seals.

The translational implications are notable. Unlike neuronal risk genes such as ICA1L and WDR12, which act intracellularly, LAMC1 is an extracellular matrix protein secreted by astrocytes and endothelial cells, making it a more accessible drug target. The authors suggest strategies such as blocking matrix metalloproteinase-mediated degradation to stabilize endogenous LAMC1, or administering recombinant laminin mimetics during the acute phase, potentially targeted at patients genetically stratified as low LAMC1 expressers. Important questions remain, including which proteases drive LAMC1 degradation and how environmental factors like chronic hypertension interact with genetic risk. But the study delivers something hemorrhagic stroke research has rarely had: a genetically validated, mechanistically explained, experimentally confirmed protective target, and a demonstration that shoring up the neurovascular unit from the astrocyte side may be a viable way to blunt the deadliest stroke of all.

Subject of Research: Genetic and cell-type-specific mechanisms of protection against intracerebral hemorrhage mediated by astrocyte-derived LAMC1

Article Title: Astrocyte-derived LAMC1 protects against intracerebral hemorrhage: A novel genetic mechanism maintaining neurovascular integrity

Article References: Cao, L., Zhang, Y., Pi, W., Zhang, R., Zhang, Y., Yong, V., & Xue, M. (2026). Astrocyte-derived LAMC1 protects against intracerebral hemorrhage: A novel genetic mechanism maintaining neurovascular integrity. Journal of Advanced Research, 88, 867-884. https://doi.org/10.1016/j.jare.2026.01.028

Image Credits: AI Generated

DOI: 10.1016/j.jare.2026.01.028

Keywords: intracerebral hemorrhage, LAMC1, astrocytes, blood-brain barrier, Mendelian randomization, colocalization analysis, single-cell eQTL, tight junction proteins, laminin, stroke genetics, neuroinflammation, gene therapy

The intestinal epithelial barrier is the body’s frontline customs office, a single layer of cells that decides what passes from the gut lumen into the bloodstream and what stays out. Its defining feature is the tight junction, a belt of protein complexes that seals the gaps between neighboring epithelial cells. These junctions perform what biologists call a gate-and-fence function: they permit the selective passage of water, ions, and nutrients through the spaces between cells while blocking bacteria and their toxins. When tight junctions fail, the result is the condition popularly known as leaky gut, in which unwanted molecules slip through and provoke inflammatory responses. Disrupted barrier function is implicated in inflammatory bowel disease, metabolic disorders, and a growing list of chronic conditions.

The key players at these junctions are the tight junction proteins, including occludin and members of the claudin family. Occludin, the first of these proteins to be identified, stabilizes the structural framework of the junction. Claudin-2, one of several tissue-specific isoforms, is associated with permeability properties of the intestinal epithelium, and its behavior is subtle: depending on context, it can either loosen or remodel the barrier. Another important player is lipocalin-2, an antibacterial, iron-sequestering protein of innate immunity that participates in the barrier’s defensive repertoire and is often induced by inflammatory stimuli. The inflammatory cytokine tumor necrosis factor alpha, meanwhile, can undermine the barrier by triggering the internalization of occludin, raising permeability.

Probiotic lactobacilli have repeatedly been shown to bolster this system. Certain strains of Lactiplantibacillus plantarum increase the production and correct localization of tight junction proteins by upregulating the genes that encode them, thereby reducing permeability and guarding against inflammation. Researchers have also explored postbiotics, the cell-free supernatants left behind after bacterial growth, which contain the bioactive metabolites of probiotic cultures without the living cells themselves. What has remained murky is how the food matrix itself contributes when probiotics are delivered as part of a fermented food, rather than as a purified supplement. The new study set out to probe exactly that boundary.

The team, led by Jihen Missaoui with colleagues at the University of Bari Aldo Moro in Italy and the University of Monastir in Tunisia, worked with two lactobacilli previously isolated from traditional zgougou: Lactiplantibacillus paraplantarum A1 and Lactiplantibacillus plantarum A2. They prepared these bacteria in three forms: living cell biomass from liquid culture, cell-free supernatant from the same cultures, and zgougou juice fermented with both strains together as a starter consortium. For comparison, they also prepared zgougou juice that had fermented spontaneously, relying on whatever microbes happened to be present. Each preparation was applied to monolayers of Caco-2 cells, a human colon cancer cell line that, when grown for 21 days on Transwell inserts, differentiates into a faithful in vitro model of the intestinal epithelium.

To gauge barrier integrity, the researchers measured transepithelial electrical resistance, or TEER, a standard technique in which a small current is passed across the cell layer; higher resistance means tighter junctions and a less permeable barrier. As a positive control, they challenged cells with lipopolysaccharide, a component of the outer membrane of E. coli that reliably disrupts tight junctions. The LPS treatment produced the expected time-dependent response, with resistance dropping significantly within 30 minutes before partially recovering. Against this baseline, the effects of the bacterial preparations emerged clearly, though not uniformly.

Exposure to the biomass of L. paraplantarum A1 raised TEER values significantly at early time points, an effect that depended on both the dose and the dilution used. The cell-free supernatant of the same strain increased resistance after six hours, and the biomass and supernatant of L. plantarum A2 produced significant boosts at 30 minutes. The most striking result, however, came from the fermented food itself. When the monolayers were treated with zgougou juice fermented by the two lactobacilli together, diluted tenfold, TEER values climbed to between roughly 690 and 963 ohms per square centimeter at every time point measured, dramatically higher than the untreated control. Spontaneously fermented juice produced a smaller but still significant effect at one time point. The combination of the two strains, embedded in the pine seed matrix, outperformed anything the bacteria achieved alone.

The molecular story behind these measurements proved equally intriguing. Using reverse transcription quantitative PCR, the team measured the expression of genes encoding occludin, claudin-2, lipocalin-2, and TNF alpha after 24 hours of exposure. Both bacterial biomasses and the driven-fermented juice significantly increased TNF alpha gene expression, yet an ELISA assay of the culture medium detected no corresponding increase in the protein itself. The authors attribute this discrepancy to post-transcriptional regulatory mechanisms that can block cytokine synthesis even when the gene is actively transcribed, a reminder that messenger RNA levels do not always translate into protein output.

More encouraging were the tight junction results. Biomass and cell-free supernatant of both lactobacilli significantly upregulated the genes for occludin and lipocalin-2, with the strongest effects seen at the tenfold dilution. The fermented zgougou juice, whether driven by the starter cultures or fermented spontaneously, significantly increased expression of both claudin-2 and occludin, with the spontaneous juice producing the strongest upregulation. The apparent tension between rising claudin-2 expression and rising TEER, which might seem contradictory given claudin-2’s association with permeability, is resolved by context: the functional impact of claudin-2 depends on the overall composition of the junction complex, and its overexpression here likely signals junction remodeling and epithelial homeostasis rather than a leaky barrier.

The authors hypothesize that the observed effects arise from a synergy between the bioactive compounds of Aleppo pine seeds, which are rich in linoleic and alpha-linolenic acids, flavonoids, and phenolics with antioxidant and anti-inflammatory activity, and the metabolic activity of the fermenting lactobacilli. Vegetable matrices may also protect probiotic bacteria during their passage through the stomach and small intestine, releasing them in the colon where they can interact directly with the host. The study is the first to show that fermented zgougou juice can upregulate genes encoding tight junction proteins in an intestinal cell model, and it underscores how traditional fermented foods, from kefir to kimchi, may modulate gut permeability through the combined action of microbes, their metabolites, and plant phytochemicals. The researchers caution that the effects are strain-dependent and shaped by the host and its resident microbiota, and they call for untargeted metabolomics to identify the specific compounds responsible, followed by animal studies to confirm whether the barrier-reinforcing effect survives the journey from the dish to the organism.

Subject of Research: Effects of Tunisian fermented zgougou and probiotic lactobacilli on intestinal epithelial barrier integrity in Caco-2 cell models

Article Title: Impact of Tunisian Fermented Zgougou and Related Lactobacilli on Caco‐2 Cell Barrier Integrity: Upregulation of Key Tight Junction Proteins

Article References: Missaoui, J., Liso, M., Lataoui, M., Limongelli, R., Minervini, F., Achour, L., & De Angelis, M. (2026). Impact of Tunisian Fermented Zgougou and Related Lactobacilli on Caco‐2 Cell Barrier Integrity: Upregulation of Key Tight Junction Proteins. Food Science & Nutrition, 14(10), Article e72387. https://doi.org/10.1002/fsn3.72387

Image Credits: AI Generated

DOI: 10.1002/fsn3.72387

Keywords: zgougou, Aleppo pine seeds, fermented foods, lactobacilli, probiotics, gut barrier, tight junction proteins, occludin, claudin-2, Caco-2 cells, TEER, postbiotics